Table 1.
FDA-approved HCV therapies with their recommended use.
| Drug name | FDA-approved HCV therapy | Genotype | Date approved |
|---|---|---|---|
| Victrelis® | PegIFNα/RBV for 4w + 200 mg boceprevir TID plus PegIFNα/RBV for 44 weeks. | GT-1 | May 2011 |
| Incivek® | 1125 mg telaprevir BID plus PegIFNα/RBV for 12w + PegIFNα/RBV for 12w or 36w. | GT-1 | May 2011 |
| Sovaldi® | 400 mg sofosbuvir QD + ribavirin for 12w or 24w; or 400 mg sofosbuvir QD + PegIFNα/RBV for 12w. | GT-1, GT-2, GT-3, GT-4 | Dec. 2013 |
| Olysio® | 150 mg simeprevir + 400 mg sofosbuvir QD for 12w or 24w; 150 mg simeprevir QD for 12w + PegIFNα/RBV for 24w or 48w. | GT-1, GT-4 | Nov. 2013 |
| Harvoni® | A fixed-dose combination tablet of 90 mg ledipasvir + 400 mg sofosbuvir, QD with or without ribavirin for 12 or 24 weeks. | GT-1, GT-4, GT-5, GT-6 | Oct. 2014 |
| Viekira Pak™ | Two fixed-dose combination tablets of 12.5 mg ombitasvir + 75 mg paritaprevir + 50 mg ritonavir QD plus 250 mg dasabuvir BID with or without ribavirin for 12 or 24 weeks. | GT-1 | Dec. 2014 |
| Technivie™ | Two fixed-dose combination tablets of 12.5 mg ombitasvir + 75 mg paritaprevir + 50 mg ritonavir with or without ribavirin, QD for 12 weeks. | GT-4 | July 2015 |
| Daklinza™ + Sovaldi® | 60 mg daclatasvir QD + 400 mg sofosbuvir QD with or without ribavirin for 12 weeks. | GT-1, GT-3 | July 2015 |
| Zepatier™ | A fixed-dose combination tablet of 100 mg grazoprevir QD + 50 mg elbasvir QD for 12 weeks, or with ribavirin for 12 or 16 weeks. | GT-1, GT-4 | Jan. 2016 |
| Epclusa® | A fixed-dose combination tablet of 400 mg sofosbuvir + 100 mg velpatasvir with or without ribavirin, QD for 12 weeks. | GT-1 to GT-6 | June 2016 |
Victrelis® and Incivek® were discontinued. Except for Technivie™, all the HCV therapies above could be applied to patients with cirrhosis. Sunvepra and Vanihep approved in Japan are not listed in Table 1.